Theragen Etex Co (066700) Fair Value & Analysis
Healthcare · KR · Market cap 88.6B KRW
Fair value as of: Jul 5, 2026
From 24 valuation models · updated today
Fair value updated Jul 5, 2026 — revised from 7,491 KRW to 4,221 KRW (−43.7%) since Jun 24, 2026. Share price −15.8% over the past month.
Price vs Fair Value (12 months)
12‑month range 1,930 KRW – 3,315 KRW · fair‑value band 3,166 KRW – 5,276 KRW · the 2,075 KRW price screens below the 4,221 KRW fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Theragen Etex Co (066700) currently trades at 2,075 KRW, while our model-based Fair Value estimate is 4,221 KRW — implying the stock looks roughly 103.4% undervalued today. We read business quality at 46/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Theragen Etex Co generated revenue of 189B KRW at a net margin of 3.5%. Revenue grew 13.4% year over year. Net debt stands at 5.3B KRW. Fundamentals as of Jul 5, 2026
Our scenario range runs from 3,166 KRW (bear case) to 5,276 KRW (bull case); at 2,075 KRW, the current price sits below that range. The share trades about 40% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -8% fair-value upside — at 103%, 066700 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Theragen Etex Co.,Ltd., together with its subsidiaries, engages in the research and development, production, and sale of pharmaceutical products. It offers drugs in the fields of circulatory, respiratory, digestive, antibiotics, antifungals, analgesic, endocrine and metabolic, hepatoprotective, psychotropic, urinary system, skeletal muscle, PMS, anthelmintic, nutrition, and others. The company was formerly known as Theragen Co., Ltd. and changed its name to Theragen Etex Co.,Ltd. in July 2010. Theragen Etex Co.,Ltd. was founded in 1987 and is headquartered in Seoul, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Theragen Etex Co reported revenue of 272B KRW in FY2025 versus 167B KRW in FY2021, a compound +13.0%/yr. Reported net income was 10.6B KRW in FY2025.
Is 066700 fairly valued? → Check now
Similar stocks
10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| ST Pharm Co 237690 | 119,500 KRW | 62,226 KRW | -48% |
| NatureCell Co 007390 | 30,800 KRW | 901.89 KRW | -97% |
| Oscotec Inc 039200 | 37,000 KRW | 34,117 KRW | -8% |
| DongKook Pharmaceutical Co 086450 | 18,190 KRW | 29,830 KRW | +64% |
| Kolon Life Science Inc 102940 | 43,600 KRW | 37,195 KRW | -15% |
| Komipharm International Co 041960 | 7,730 KRW | 564.06 KRW | -93% |
| BINEX Co 053030 | 6,900 KRW | 27,024 KRW | +292% |
| Anterogen.Co.,Ltd., a bio-venture company, 065660 | 20,650 KRW | 49,475 KRW | +140% |
| Vivozon Pharmaceutical Co 082800 | 2,765 KRW | 2,928 KRW | +6% |
| EURO EURO | 1.07 PHP | 0.7800 PHP | -27% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Theragen Etex Co (066700) undervalued?
What is the fair value of 066700?
What is the quality score of 066700?
What is the revenue of Theragen Etex Co (066700)?
What is the net profit margin of 066700?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.